Cargando…

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bohan, Liu, Yachong, Liao, Zhibin, Wu, Haofeng, Zhang, Bixiang, Zhang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236851/ https://www.ncbi.nlm.nih.gov/pubmed/37268997 http://dx.doi.org/10.1186/s40164-023-00405-2

Ejemplares similares

The role of YAP1 in liver cancer stem cells: proven and potential mechanisms
por: Wu, Haofeng, et al.
Publicado: (2022)

A micropeptide JunBP regulated by TGF-β promotes hepatocellular carcinoma metastasis
por: Zhang, Hongwei, et al.
Publicado: (2022)

ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner
por: Wang, Weijian, et al.
Publicado: (2023)

Long noncoding RNA HOXC-AS3 interacts with CDK2 to promote proliferation in hepatocellular carcinoma
por: Su, Chen, et al.
Publicado: (2022)

Long noncoding RNA SNHG14 promotes hepatocellular carcinoma progression by regulating miR-876-5p/SSR2 axis
por: Liao, Zhibin, et al.
Publicado: (2021)

EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway
por: Liu, Yachong, et al.
Publicado: (2022)

ALKBH5-mediated m(6)A modification of lincRNA LINC02551 enhances the stability of DDX24 to promote hepatocellular carcinoma growth and metastasis
por: Zhang, Hongwei, et al.
Publicado: (2022)

Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy
por: Bae, An-Na, et al.
Publicado: (2022)

Long noncoding RNA HULC promotes hepatocellular carcinoma progression
por: Zhang, Hongwei, et al.
Publicado: (2019)

Long non-coding RNA CCDC183-AS1 acts AS a miR-589-5p sponge to promote the progression of hepatocellular carcinoma through regulating SKP1 expression
por: Zhu, He, et al.
Publicado: (2021)

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
por: Wu, Shi-yi, et al.
Publicado: (2022)

Circular RNA circUBE2J2 acts as the sponge of microRNA-370-5P to suppress hepatocellular carcinoma progression
por: Zhang, Lu, et al.
Publicado: (2021)

miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE
por: Chen, Bingqing, et al.
Publicado: (2020)

Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma
por: Liu, Furong, et al.
Publicado: (2020)

Modulation of the TGF-β signaling pathway by long noncoding RNA in hepatocellular carcinoma
por: Han, Mengzhen, et al.
Publicado: (2020)

Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression
por: Liu, Furong, et al.
Publicado: (2023)

Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma
por: Tan, Xiaolong, et al.
Publicado: (2018)

Targeting EZH2 for Cancer Therapy: Progress and Perspective
por: Li, Chi Han, et al.
Publicado: (2015)

Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma
por: Li, Xinxin, et al.
Publicado: (2022)

LINC01419 facilitates hepatocellular carcinoma growth and metastasis through targeting EZH2-regulated RECK
por: Zhang, Gong, et al.
Publicado: (2020)

EZH2 as a Potential Target for NAFLD Therapy
por: Lim, Hyun Jung, et al.
Publicado: (2020)

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
por: Yan, Ke-Sin, et al.
Publicado: (2017)

EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma
por: Xu, Shan, et al.
Publicado: (2023)

Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma
por: Xie, Cheng-Rong, et al.
Publicado: (2015)

EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis
por: Chen, Shaofei, et al.
Publicado: (2018)

CRISPR/Cas9‐mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV‐positive hepatocellular carcinoma cells
por: Song, Jia, et al.
Publicado: (2018)

LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression
por: Xu, Xueying, et al.
Publicado: (2019)

MicroRNA-20a Suppresses Tumor Proliferation and Metastasis in Hepatocellular Carcinoma by Directly Targeting EZH1
por: Zhang, Qianqian, et al.
Publicado: (2021)

Hypoxia-Induced Placenta-Specific microRNA (miR-512-3p) Promotes Hepatocellular Carcinoma Progression by Targeting Large Tumor Suppressor Kinase 2
por: Zhang, Bohan, et al.
Publicado: (2020)

EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target
por: Lin, Zhuangling, et al.
Publicado: (2023)

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
por: Xiao, Gang, et al.
Publicado: (2019)

Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
por: Liu, Ziyu, et al.
Publicado: (2019)

Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma
por: Yu, Yung-Luen, et al.
Publicado: (2013)

Aberrant Upregulation of 14-3-3σ and EZH2 Expression Serves as an Inferior Prognostic Biomarker for Hepatocellular Carcinoma
por: Zhang, Yi, et al.
Publicado: (2014)

The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis
por: Zhai, Run, et al.
Publicado: (2016)

TRIM proteins in hepatocellular carcinoma
por: Lu, Kan, et al.
Publicado: (2022)

P53 suppresses the progression of hepatocellular carcinoma via miR‐15a by decreasing OGT expression and EZH2 stabilization
por: You, Zhenyu, et al.
Publicado: (2021)

DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma
por: Shi, Min, et al.
Publicado: (2017)

Ruptured Hepatocellular Carcinoma: Current Status of Research
por: Xia, Feng, et al.
Publicado: (2022)

Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
por: Sudo, T, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_u9irg4m6obkqo8hqulb80iikan